Center for Scientific Review; Notice of Closed Meetings, 65183-65184 [2023-20437]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 182 / Thursday, September 21, 2023 / Notices
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: October 27, 2023.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G13A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mairi Noverr, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activitie,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G13A, Rockville, MD
20852, (240) 747–7530, mairi.noverr@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 15, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20421 Filed 9–20–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing and
Collaboration
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention described
below presents an advancement
concerning osteoclast fusion; osteoclasts
are responsible for human skeletal
remodeling and their dysfunction is a
key factor for both rare and common
bone diseases. The invention covers
methods for modulating osteoclast
fusion and bone resorption through the
Lupus autoantigen (La) protein. The
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development (NICHD), National
Institutes of Health, has conducted
conceptual in-vitro studies and is now
seeking potential licensees and
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:11 Sep 20, 2023
Jkt 259001
collaborators for further development
and advancement.
ADDRESSES: Inquiries relating to this
licensing and collaboration opportunity
should be directed to: Heather Gunas,
JD, MPH, Senior Technology Transfer
Manager, National Cancer Institute
(NCI) Technology Transfer Center, 9609
Medical Center Drive, Room 1E446,
Rockville, MD 20850 (for overnight
mail) or Bethesda, MD 20892 (for
regular mail), Telephone: (240) 276–
5530; Facsimile: (240) 276–5504; Email:
gunash@mail.nih.gov. A Confidential
Disclosure Agreement will be required
to receive copies of unpublished
information regarding this invention.
SUPPLEMENTARY INFORMATION: The
following and all continuing U.S. and
foreign patents/patent applications
thereof are available for licensing: PCT
Application No. PCT/US22/018639,
filed March 3, 2022, and entitled ‘‘La
protein as a novel regulator of
osteoclastogenesis.’’ The Lupus
autoantigen (La) protein is a master
regulator of osteoclasts. The technology
involves a novel mechanism for precise
regulation of osteoclastogenesis through
the manipulation of surface La protein.
The ability of osteoclasts to remodel
bone can be modulated by: (1)
administering an effective amount of La
protein or (2) administering an agent
that modulates La protein expression or
activity. Current solutions for bone
diseases are usually broad-spectrum
treatments that either coat the skeletal
system or inhibit osteoclast
development and these approaches can
result in off-target side effects. This
technology’s approach to regulating
osteoclast fusion and osteoclastogenesis
by targeting the La protein should
bypass many side effects. The
technology has been supported by
conceptual in-vitro data and lead
optimization is ongoing; further
research and development are required
to advance it towards disease-specific
preclinical and clinical stages.
Potential Commercial Application:
Treatment of common and rare bone
diseases, including osteoporosis, Paget’s
disease of bone, fibrous dysplasia,
rheumatoid arthritis, osteopetrosis,
osteomyelitis, or metastatic bone
disease.
Development Stage: In-vitro study
completed and lead optimization
ongoing.
Dated: September 18, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2023–20479 Filed 9–20–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
65183
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Social and Environmental Determinants of
Health Study Section.
Date: October 18–19, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ananya Paria, DHSC,
MPH, MS, Scientific Review Officer, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1007H,
Bethesda, MD 20892, (301) 827–6513,
pariaa@mail.nih.gov.
Name of Committee: Digestive, Kidney and
Urological Systems Integrated Review Group;
Digestive and Nutrient Physiology and
Diseases Study Section.
Date: October 19–20, 2023.
Time: 9:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Aster Juan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20817, 301–435–5000, juana2@mail.nih.gov.
Name of Committee: Endocrinology,
Metabolism, Nutrition and Reproductive
Sciences Integrated Review Group; Human
Studies of Diabetes and Obesity Study
Section.
Date: October 19–20, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Hui Chen, MD, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
E:\FR\FM\21SEN1.SGM
21SEN1
65184
Federal Register / Vol. 88, No. 182 / Thursday, September 21, 2023 / Notices
Drive, Room 6164, Bethesda, MD 20892,
(301) 435–1044, chenhui@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 15, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20437 Filed 9–20–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meetings
ddrumheller on DSK120RN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; K99–U24–R13 SEP.
Date: November 3, 2023.
Time: 2:30 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Human Genome Research Institute,
6700B Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sarah Jo Wheelan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, MSC 6908, Bethesda, MD
20892, (301) 402–8823, wheelansj@nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel SEP–1 K99 HG013541–01 Member
Conflict.
Date: November 3, 2023.
Time: 6:15 p.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Human Genome Research Institute,
6700B Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sarah Jo Wheelan, Ph.D.,
Scientific Review Officer, Scientific Review
VerDate Sep<11>2014
17:11 Sep 20, 2023
Jkt 259001
Branch, National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, MSC 6908, Bethesda, MD
20892, (301) 402–8823, wheelansj@nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Diversity Centers.
Date: November 16, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Human Genome Research Institute,
6700B Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Rudy O. Pozzatti, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, MSC 6908, Bethesda, MD
20892, (301) 402–8739, pozzattr@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: September 18, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20490 Filed 9–20–23; 8:45 am]
BILLING CODE 4140–01–P
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 205–H,
Bethesda, MD 20892, (301) 827–7969,
Pintuccig@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: September 18, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20492 Filed 9–20–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency
Coordinating Committee Meeting
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Diabetes Mellitus
Interagency Coordinating Committee
(DMICC) will hold a meeting on
November 16, 2023. The topic for this
meeting will be ‘‘The Application of
Digital Health Technology to Type 2
Diabetes Management: Current Status,
Research Gaps, and Opportunities’’. The
meeting is open to the public.
DATES: The meeting will be held on
November 16, 2023 from 12:00 p.m. to
4:00 p.m. EST.
ADDRESSES: The meeting will be held
via the Zoom online video conferencing
platform. For details, and to register,
please contact dmicc@mail.nih.gov.
FOR FURTHER INFORMATION CONTACT: For
further information concerning this
meeting, including a draft agenda,
which will be posted when available,
see the DMICC website,
www.diabetescommittee.gov, or contact
Dr. William Cefalu, Executive Secretary
of the Diabetes Mellitus Interagency
Coordinating Committee, National
Institute of Diabetes and Digestive and
Kidney Diseases, 6707 Democracy
Boulevard, Democracy 2, Room 6037,
Bethesda, MD 20892, telephone: 301–
435–1011; email: dmicc@mail.nih.gov.
SUPPLEMENTARY INFORMATION: In
accordance with 42 U.S. Code 285c–3,
the DMICC, chaired by the National
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) comprising
members of the Department of Health
and Human Services and other federal
agencies that support diabetes-related
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, And Blood
Institute; Notice of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; NHLBI
Mentored Transition to Independence Study
Section.
Date: November 16–17, 2023.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Canopy by Hilton, Washington,
DC, Bethesda North, 940 Rose Avenue, North
Bethesda, MD 20892 (Hybrid Meeting).
Contact Person: Giuseppe Pintucci, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
E:\FR\FM\21SEN1.SGM
21SEN1
]]>Agencies
[Federal Register Volume 88, Number 182 (Thursday, September 21, 2023)]
[Notices]
[Pages 65183-65184]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-20437]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Population Sciences and Epidemiology
Integrated Review Group; Social and Environmental Determinants of
Health Study Section.
Date: October 18-19, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ananya Paria, DHSC, MPH, MS, Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1007H, Bethesda, MD 20892, (301)
827-6513, [email protected].
Name of Committee: Digestive, Kidney and Urological Systems
Integrated Review Group; Digestive and Nutrient Physiology and
Diseases Study Section.
Date: October 19-20, 2023.
Time: 9:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Aster Juan, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20817, 301-435-5000,
[email protected].
Name of Committee: Endocrinology, Metabolism, Nutrition and
Reproductive Sciences Integrated Review Group; Human Studies of
Diabetes and Obesity Study Section.
Date: October 19-20, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Hui Chen, MD, Scientific Review Officer, Center
for Scientific Review, National Institutes of Health, 6701 Rockledge
[[Page 65184]]
Drive, Room 6164, Bethesda, MD 20892, (301) 435-1044,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: September 15, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-20437 Filed 9-20-23; 8:45 am]
BILLING CODE 4140-01-P
